Platelet function testing in patients on antiplatelet medications

Seminars in Thrombosis and Hemostasis

Volumn 42, Issue 3, 2016, Pages 306-320

  Gross, Lisa ^a   Aradi, Dániel ^b,c   Sibbing, Dirk ^a,d  

^a UNIVERSITY OF MUNICH   (Germany)

^b Department of Cardiology   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

guidance of treatment; high on treatment platelet reactivity; low on treatment platelet reactivity; platelet function testing; risk prediction; stent thrombosis; tailored antiplatelet therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ARTICLE; BLEEDING; HEART MUSCLE ISCHEMIA; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT THROMBOSIS; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; THROMBOCYTE FUNCTION TESTING; BLOOD CLOTTING PARAMETERS; CHEMICALLY INDUCED; DRUG EFFECTS; HEMORRHAGE; PHYSIOLOGY; PROCEDURES; RISK FACTOR; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOSIS;

BLOOD PLATELETS; HEMORRHAGE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK FACTORS; THROMBOSIS;

EID: 84958780864     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1570083     Document Type: Article

References (87)

1. Windecker S., Kolh P., Alfonso F., et al. Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J: 2014; 35 37 2541 2619
2. Mehta S. R., Yusuf S., Peters R. J., et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet: 2001; 358 9281 527 533
3. Bonello L., Tantry U. S., Marcucci R., et al. Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol: 2010; 56 12 919 933
4. Angiolillo D. J., Fernandez-Ortiz A., Bernardo E., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol: 2007; 49 14 1505 1516
5. Sibbing D., Koch W., Gebhard D., et al. Cytochrome 2C19∗17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation: 2010; 121 4 512 518
6. Sibbing D., Steinhubl S. R., Schulz S., Schömig A., Kastrati A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol: 2010; 56 4 317 318
7. Gurbel P. A., Bliden K. P. Platelet activation after stenting with heparin-coated versus noncoated stents. Am Heart J: 2003; 146 4 E10
8. Serebruany V. L., Steinhubl S. R., Berger P. B., Malinin A. I., Bhatt D. L., Topol E. J. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol: 2005; 45 2 246 251
9. Holmes M. V., Perel P., Shah T., Hingorani A. D., Casas J. P. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA: 2011; 306 24 2704 2714
10. Mega J. L., Simon T., Collet J. P., et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA: 2010; 304 16 1821 1830
11. Geisler T., Anders N., Paterok M., et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care: 2007; 30 2 372 374
12. Frelinger A. L. III, Bhatt D. L., Lee R. D., et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol: 2013; 61 8 872 879
13. Wiviott S. D., Trenk D., Frelinger A. L., et al. PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation: 2007; 116 25 2923 2932
14. Gurbel P. A., Bliden K. P., Hiatt B. L., O'Connor C. M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation: 2003; 107 23 2908 2913
15. Sibbing D., Braun S., Morath T., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol: 2009; 53 10 849 856
16. Tantry U. S., Bonello L., Aradi D., et al. Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol: 2013; 62 24 2261 2273
17. Aradi D., Kirtane A., Bonello L., et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J: 2015; 36 27 1762 1771
18. Breet N. J., van Werkum J. W., Bouman H. J., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA: 2010; 303 8 754 762
19. Serebruany V. L., Aradi D., Kim M. H., Sibbing D. Cangrelor infusion is associated with an increased risk for bleeding: meta-analysis of randomized trials. Int J Cardiol: 2013; 169 3 225 228
20. Morrow D. A., Braunwald E., Bonaca M. P., et al. TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med: 2012; 366 15 1404 1413
21. Chhatriwalla A. K., Amin A. P., Kennedy K. F., et al. National Cardiovascular Data Registry. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA: 2013; 309 10 1022 1029
22. Michelson A. D., Frelinger A. L. III, Braunwald E., et al. TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J: 2009; 30 14 1753 1763
23. Bonello L., Mancini J., Pansieri M., et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost: 2012; 10 10 1999 2005
24. Cuisset T., Grosdidier C., Loundou A. D., et al. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). JACC Cardiovasc Interv: 2013; 6 8 854 863
25. Parodi G., Bellandi B., Venditti F., et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am J Cardiol: 2012; 109 2 214 218
26. Bonaca M. P., Bhatt D. L., Cohen M., et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med: 2015; 372 19 1791 1800
27. Kazi D. S., Leong T. K., Chang T. I., Solomon M. D., Hlatky M. A., Go A. S. Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention. J Am Coll Cardiol: 2015; 65 14 1411 1420
28. Mayer K., Bernlochner I., Braun S., et al. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. J Am Coll Cardiol: 2014; 64 9 863 871
29. Kovács E. G., Katona E., Bereczky Z., et al. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals. Thromb Res: 2013; 131 4 320 324
30. Kovács E. G., Katona É, Bereczky Z., et al. Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods. Thromb Res: 2014; 133 5 811 816
31. Paniccia R., Priora R., Liotta A. A., Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag: 2015; 11 133 148
32. Siller-Matula J. M., Trenk D., Schrör K., et al. EPA (European Platelet Academy). Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv: 2013; 6 11 1111 1128
33. Lordkipanidze M. Platelet function tests. Semin Thromb Hemost: 2016
34. Aradi D., Storey R. F., Komócsi A., et al. Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J: 2014; 35 4 209 215
35. Breet N. J., van Werkum J. W., Bouman H. J., Kelder J. C., Ten Berg J. M., Hackeng C. M. High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost: 2010; 8 10 2140 2148
36. Stone G. W., Witzenbichler B., Weisz G., et al. ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet: 2013; 382 9892 614 623
37. Pettersen A. A., Seljeflot I., Abdelnoor M., Arnesen H. High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Assoc: 2012; 1 3 e000703
38. Mehta S. R., Tanguay J. F., Eikelboom J. W., et al. CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet: 2010; 376 9748 1233 1243
39. Cuisset T., Frere C., Quilici J., et al. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. Am J Cardiol: 2009; 104 8 1078 1082
40. Parodi G., Marcucci R., Valenti R., et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA: 2011; 306 11 1215 1223
41. Geisler T., Langer H., Wydymus M., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J: 2006; 27 20 2420 2425
42. Hochholzer W., Trenk D., Bestehorn H. P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol: 2006; 48 9 1742 1750
43. Angiolillo D. J., Bernardo E., Sabaté M., et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol: 2007; 50 16 1541 1547
44. Aradi D., Komócsi A., Vorobcsuk A., et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J: 2010; 160 3 543 551
45. Combescure C., Fontana P., Mallouk N., et al. CLOpidogrel and Vascular ISchemic Events Meta-analysis Study Group. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost: 2010; 8 5 923 933
46. Sofi F., Marcucci R., Gori A. M., Giusti B., Abbate R., Gensini G. F. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost: 2010; 103 4 841 848
47. Brar S. S., ten Berg J., Marcucci R., et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol: 2011; 58 19 1945 1954
48. Snoep J. D., Hovens M. M., Eikenboom J. C., van der Bom J. G., Jukema J. W., Huisman M. V. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J: 2007; 154 2 221 231
49. Alexopoulos D., Galati A., Xanthopoulou I., et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol: 2012; 60 3 193 199
50. Parodi G., Valenti R., Bellandi B., et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol: 2013; 61 15 1601 1606
51. Wallentin L., Varenhorst C., James S., et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J: 2008; 29 1 21 30
52. Collet J. P., Cuisset T., Rangé G., et al. ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med: 2012; 367 22 2100 2109
53. Price M. J., Berger P. B., Teirstein P. S., et al. GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA: 2011; 305 11 1097 1105
54. Serebruany V., Rao S. V., Silva M. A., et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J: 2010; 31 2 227 235
55. Cayla G., Cuisset T., Silvain J., et al. Prasugrel monitoring and bleeding in real world patients. Am J Cardiol: 2013; 111 1 38 44
56. Patti G., Pasceri V., Vizzi V., Ricottini E., Di Sciascio G. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol: 2011; 107 7 995 1000
57. Mokhtar O. A., Lemesle G., Armero S., et al. Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thromb Res: 2010; 126 2 e147 e149
58. Grosdidier C., Quilici J., Loosveld M., et al. Effect of CYP2C19∗2 and∗17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am J Cardiol: 2013; 111 7 985 990
59. Sibbing D., Schulz S., Braun S., et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost: 2010; 8 2 250 256
60. Campo G., Parrinello G., Ferraresi P., et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol: 2011; 57 25 2474 2483
61. Mangiacapra F., Patti G., Barbato E., et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv: 2012; 5 3 281 289
62. Gurbel P. A., Bliden K. P., Navickas I. A., et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J: 2010; 160 2 346 354
63. Gurbel P. A., Becker R. C., Mann K. G., Steinhubl S. R., Michelson A. D. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol: 2007; 50 19 1822 1834
64. Palmerini T., Calabrò P., Piscione F., et al. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study. JACC Cardiovasc Interv: 2014; 7 10 1117 1127
65. Mangiacapra F., Ricottini E., Barbato E., et al. Incremental value of platelet reactivity over a risk score of clinical and procedural variables in predicting bleeding after percutaneous coronary intervention via the femoral approach: development and validation of a new bleeding risk score. Circ Cardiovasc Interv: 2015; 8 5 8
66. Trenk D., Stone G. W., Gawaz M., et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol: 2012; 59 24 2159 2164
67. Price M. J., Angiolillo D. J., Teirstein P. S., et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation: 2011; 124 10 1132 1137
68. Mayer K., Schulz S., Bernlochner I., et al. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Thromb Haemost: 2014; 112 2 342 351
69. Aradi D., Tornyos A., Pintér T., et al. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol: 2014; 63 11 1061 1070
70. Siller-Matula J. M., Francesconi M., Dechant C., et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol: 2013; 167 5 2018 2023
71. Antman E. M., Wiviott S. D., Murphy S. A., et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol: 2008; 51 21 2028 2033
72. Roffi M., Patrono C., Collet J. P., et al. Authors/Task Force M. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J: 2016; 14;37 3 267 315
73. Bonello L., Paganelli F., Arpin-Bornet M., et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost: 2007; 5 8 1630 1636
74. Campo G., Fileti L., de Cesare N., et al. 3T/2R Investigators. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol: 2010; 56 18 1447 1455
75. Frere C., Cuisset T., Quilici J., et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost: 2007; 98 4 838 843
76. Gurbel P. A., Antonino M. J., Bliden K. P., et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets: 2008; 19 8 595 604
77. Marcucci R., Gori A. M., Paniccia R., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation: 2009; 119 2 237 242
78. Price M. J., Endemann S., Gollapudi R. R., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J: 2008; 29 8 992 1000
79. Sibbing D., Bernlochner I., Schulz S., et al. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. J Am Coll Cardiol: 2012; 60 5 369 377
80. Yamaguchi Y., Abe T., Sato Y., Matsubara Y., Moriki T., Murata M. Effects of VerifyNow P2Y12 test and CYP2C19∗2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis. Platelets: 2013; 24 5 352 361
81. Cuisset T., Cayla G., Frere C., et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention: 2009; 5 3 325 329
82. Tsukahara K., Kimura K., Morita S., et al. Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. Circ J: 2010; 74 4 679 685
83. Bonello L., Camoin-Jau L., Armero S., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol: 2009; 103 1 5 10
84. Wang X. D., Zhang D. F., Zhuang S. W., Lai Y. Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clin Cardiol: 2011; 34 5 332 338
85. Ari H., Ozkan H., Karacinar A., Ari S., Koca V., Bozat T. The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial). Int J Cardiol: 2012; 157 3 374 380
86. Hazarbasanov D., Velchev V., Finkov B., et al. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. J Thromb Thrombolysis: 2012; 34 1 85 90
87. Mrdovic I., Savic L., Krljanac G., et al. Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial. J Interv Cardiol: 2013; 26 3 221 227